Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DREAMM-20: Belantamab ± belantamab mafodotin in relapsed/refractory multiple myeloma
jRCT2051230065Phase 2Recruiting
- Sponsor
- GSK
- Start
- Aug 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 2, open-label trial of belantamab in multiple myeloma (MM) (2 arms), sponsored by GSK. Primary endpoints: Number of participants with any adverse event, Number of participants with worst case grade change from baseline in laboratory and vital sign parameters and 3 more. Started Aug 2023; status: recruiting.
02
Drugs
belantamab
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on jRCT2051230065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051230065.